- Daniel Naranjo
- Associate Medical Director
Daniel Naranjo has been in the pharmaceutical industry for 5 years, most recently he is serving as the Global Safety Lead for cell therapies and developmental products at Takeda Oncology. He received his medical degree from Aureus University and subsequently worked in clinical research in across several therapeutic areas to include: neuroradiology, neurology, and cardiology. In 2014 he moved his career to the pharmaceutical industry, joining Fresenius, where she had a successful career in drug and safety by establishing and harmonizing medical safety across drugs and devices for 2 years at Fresenius. In 2017,he joined Takeda and pioneered a variety of safety initiatives aimed at resolving cardiovascular risk in oncology products. He led endpoint adjudication workstreams and has also pioneered the use of safety biomarkers to identify and predict cardiovascular risk in patients throughout clinical studies. Daniel leads global safety and risk management for cell therapies within Takeda and has a passion for solving complex safety issues and enjoys being at the forefront of new safety initiatives which leverage the integration of predictive analytics, biomarkers and big data in benefit risk evaluation.
Daniel previously worked at Merrill Lynch and is a United States Marine Corps combat veteran.